press releases

Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer

Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer 150 150 Lysogene

Paris, France — 03 February 2023 at 6:00 pm CET — Lysogene (FR0013233475 – LYS), a…

Lysogene: conversion of the safeguard proceedings into reorganization proceedings

Lysogene: conversion of the safeguard proceedings into reorganization proceedings 150 150 Lysogene

Paris, France — 25 January 2023 at 08:00 am CET —Lysogene (FR0013233475 – LYS), a phase…

Lysogene: launch of a process to find buyers or investors and request for conversion of safeguard proceedings into reorganization proceedings

Lysogene: launch of a process to find buyers or investors and request for conversion of safeguard proceedings into reorganization proceedings 150 150 Lysogene

Paris, France — 6 January 2023 at 05:00 pm CET —Lysogene (FR0013233475 – LYS), a…

Lysogene announces the opening of a safeguard proceeding

Lysogene announces the opening of a safeguard proceeding 150 150 Lysogene

Paris, France — 14 December 2022 at 08:00 am CET — Lysogene (FR0013233475 – LYS),…

Lysogene announces the request for the opening of a safeguard proceeding

Lysogene announces the request for the opening of a safeguard proceeding 150 150 Lysogene

Paris, France — 6 December 2022 — Lysogene (FR0013233475 – LYS), a phase 3 gene…

Lysogene Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis

Lysogene Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis 150 150 Lysogene

Completion of treatment and 6 months follow-up for the last patient enrolled in Stage 1…

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study 150 150 Lysogene

In the cohort of patients enrolled before the age of 30 months, a statistically significant…

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 150 150 Lysogene

Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET Paris,…

Lysogene Reports its Cash Position as of 30 September 2022

Lysogene Reports its Cash Position as of 30 September 2022 150 150 Lysogene

Cash and cash equivalents of €6.1 million[1] as of 30 September 2022 Paris, France —…

Lysogene Reports First Half 2022 Financial Results

Lysogene Reports First Half 2022 Financial Results 150 150 Lysogene

Full data analysis of AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in MPS…

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.